CJC-1295 without DAC + Ipamorelin (Blend)
This blend combines CJC-1295 without DAC and ipamorelin in a single vial, pairing two different growth-hormone-releasing signals for a stronger combined pulse than either peptide delivers alone. It's used in the same bodybuilding, anti-aging, and recovery protocols as its two component peptides, sold premixed for convenience. It's one of the most popular growth-hormone secretagogue combinations on the market.
$200 / 20 mg vial
Dosing
Community reported
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Weeks 1-2 | 100 mcg each | once daily | Starting dose1 |
| Weeks 3-4 | 150 mcg each | once daily | |
| Weeks 5-6 | 200 mcg each | once daily | |
| Weeks 7-12 | 250-300 mcg each | once daily | Maintenance23 |
- Subcutaneous, before bed or on waking, fasted state preferred. Optional extension to 16 weeks.
- Assumes the site's 1:1, 5 mg/5 mg (10 mg total) vial; a different total mg or ratio requires rescaling proportionally, not applying these numbers as absolute. Community threads show real confusion between dosing off the 5 mg per-peptide figure versus the vial's combined 10 mg label.
- No dosing study of this specific two-peptide combination has been published; this schedule is peptidedosages.com's own blend convention, not derived from a controlled trial of the combination. For each component's own individually studied dosing, see the separate CJC-1295 without DAC and Ipamorelin catalog entries.
Batches on hand
Availability
30 vials on hand.
MKM-CP20-26072630 vials
Full research
Evidence tier
Anecdotal, no controlled data
No controlled study of this specific two-component combination was located in either component's own underlying research. Each component individually has its own, materially different, evidence base: CJC-1295 without DAC's only controlled study is a 2005 rat pituitary-receptor-activation study (see that entry, tier: Animal and in-vitro only), and Ipamorelin has early human pharmacodynamic data plus one negative-indication RCT in an unrelated condition (see that entry, tier: Early human data only). Applying either component's own tier to this blend would overstate the evidence that actually exists for the combination specifically. What is documented and citable at the combination level is only the general pharmacological rationale for stacking a GHRH analog with a ghrelin-receptor agonist, plus anecdotal community and vendor use of premixed products like this one, hence the lowest tier applies to the blend itself.
Identity
| Full name | A combination product: Modified GRF(1-29), also called CJC-1295 without DAC, a GHRH-receptor agonist, combined with Ipamorelin, a selective ghrelin-receptor (GHS-R1a) agonist, typically supplied premixed in a single vial by compounding vendors. |
|---|---|
| Class | Two-component growth hormone secretagogue blend: a GHRH-receptor agonist (CJC-1295 without DAC) paired with a ghrelin-receptor agonist (Ipamorelin). |
Mechanism of action
Plain language
This product combines two different growth-hormone-releasing signals in one vial. CJC-1295 without DAC copies the brain's GHRH signal. Ipamorelin copies a separate hormone, ghrelin, that triggers growth hormone release through its own distinct switch on the pituitary gland. Because the two work through different receptors, the combination is intended to produce a larger burst of growth hormone than either compound alone.
Technical
CJC-1295 without DAC is a GHRH-receptor (GHRHR) agonist; Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist. The two receptors converge on the same anterior-pituitary somatotroph cell through separate signaling pathways, and combining a GHRH analog with a ghrelin-receptor agonist is documented at the class level to produce pulsatile GH secretion substantially greater than either agent alone: a GHRH-plus-GHRP-2 pairing produced a 54-fold increase in pulsatile GH secretion versus 47-fold for GHRP-2 alone and 20-fold for GHRH alone. No controlled human trial of this specific two-component combination, at any dose or ratio, was located in the underlying research for either component. The pharmacological rationale for stacking these two specific agents is documented only at the class level, not for this blend directly. Full mechanism, receptor pharmacology, and citation detail for each half of this blend live on their own catalog entries: see CJC-1295 without DAC (Modified GRF 1-29) and Ipamorelin.
Sources: Jette L, et, 2005, Raun K, Hansen, 1998, Sinha et al.
Why: No combination-specific evidence
No controlled study of CJC-1295 without DAC and Ipamorelin used together has been located. Each component's own evidence base is materially different in kind and quality; see the separate CJC-1295 without DAC (Modified GRF 1-29) and Ipamorelin entries for what is actually documented about each.
Sources: Jette L, et, 2005, Raun K, Hansen, 1998
Why: Two receptors, one rationale
The pharmacological logic for stacking these two compounds is that they act on separate receptors, the GHRH receptor and the ghrelin receptor GHS-R1a, that converge on the same pituitary somatotroph cell. This synergy is documented at the class level using a different GHRH-plus-ghrelin-agonist pairing, GHRH plus GHRP-2, not for this specific combination.
Sources: Sinha et al.
Why: Doses are not summed
This catalog does not add or average the two components' individually studied or community-reported doses into a blend figure. No dosing study of the combined product exists, so any blend dose in circulation is unsourced community practice; see each component's own dosing section for what is, and is not, documented for that molecule alone.
Sources: thepeptidecatalog.com, CJC-1295 No
What it’s used for
Off-label / community use
- This premixed combination is commonly sold and self-administered in bodybuilding, anti-aging, and recovery communities on the theory that stacking a GHRH analog with a ghrelin-receptor agonist produces a larger GH pulse than either alone, extrapolating from class-level GHRH-plus-ghrelin-agonist synergy data rather than from any trial of this specific combination. See CJC-1295 without DAC and Ipamorelin for each component's own off-label community use.
Pharmacokinetics
| Blend-specific pharmacokinetics |
Not established No citable figure. No pharmacokinetic study of this specific combination exists. Each component's own pharmacokinetics, and their own respective gaps, are documented on their own entries: CJC-1295 without DAC (Modified GRF 1-29) and Ipamorelin. |
|---|
Reconstitution
Reconstitution does not apply to this compound: No blend-specific vial strength, diluent ratio, or worked reconstitution example for this premixed combination is established in the underlying research; inventing one would misstate the owner's actual vial contents. For each component's own vendor-typical vial strength and worked reconstitution arithmetic (commonly 2 mg or 5 mg lyophilized vials, generally reconstituted with bacteriostatic water), see the separate CJC-1295 without DAC (Modified GRF 1-29) and Ipamorelin entries. A compounded blend vial's actual strength and ratio should be confirmed against its own certificate of analysis or vendor label rather than assumed from either single-compound entry.
Storage and post-reconstitution stability
Unopened storage
No blend-specific storage data is established. See the CJC-1295 without DAC and Ipamorelin entries for each component's own vendor-represented storage convention (both are commonly described as refrigerated or frozen and light-protected before reconstitution, per vendor sources, not independently regulatory-validated).
Post-reconstitution stability – Not established
No citable figure. No blend-specific post-reconstitution stability data exist. See the CJC-1295 without DAC and Ipamorelin entries for each component's own vendor-claimed, not regulatory-validated, post-reconstitution stability figures, which should not be assumed to transfer unchanged to a combined formulation.
Safety
Notable risks
- No safety data exist for this specific combination administered together. Each component's own documented safety signals, and their own respective evidentiary gaps, are catalogued separately: see CJC-1295 without DAC (Modified GRF 1-29) and Ipamorelin. Combining two GH secretagogues has not been studied for additive or synergistic adverse effects, for example on IGF-1 elevation, injection-site reactions, or theoretical malignancy risk, beyond what either component's own single-agent literature reports.
Sources
- Jette L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. (2005)
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. (1998)
- Sinha et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology.
- thepeptidecatalog.com, CJC-1295 No DAC dosing guide (commercial vendor dosing guide), cited here only for the general community-stacking rationale, not for this blend specifically
- peptidedosages.com, CJC-1295 (no DAC) + Ipamorelin 10 mg blend dosage protocol
This is a research and educational reference, not medical advice. Nothing on this site is a recommendation to use any compound.